Secondary Hyperparathyroidism
Endocrine
Secondary Hyperparathyroidism is treated with 9 medications in our database, including Cinacalcet, Paricalcitol, Zemplar, Calcitriol, Doxercalciferol, and 4 more. 6 of these have manufacturer assistance programs available to help reduce out-of-pocket costs. Medications are manufactured by Amgen, AbbVie, Roche, Sanofi, OPKO Health and others. Patients and caregivers can find copay cards, patient assistance programs, and travel grants for Secondary Hyperparathyroidism treatment below.
What help exists for Secondary Hyperparathyroidism
10
drugs indexed
2
with copay cards
2
with patient assistance
0
open travel grants
Every item below links to the manufacturer's or charity's own portal. RxCopays does not take referral fees.
Drugs used to treat Secondary Hyperparathyroidism
10 totalSensipar
cinacalcet hydrochloride · Amgen
Zemplar
Paricalcitol · AbbVie
Paricalcitol
Paricalcitol · AbbVie
Rayaldee
calcifediol · OPKO Health
🎟💙CINACALCET
Cinacalcet · Amgen
PARSABIV
etelcalcetide · Amgen
🎟💙Doxercalciferol
DOXERCALCIFEROL · Sanofi
Cinacalcet Hydrochloride
Cinacalcet Hydrochloride · Amgen
Calcitriol
Calcitriol · Roche
Calcitrol
calcitriol
🎟 = copay card · 💙 = patient assistance program
Prior authorization patterns for Secondary Hyperparathyroidism drugs
Aggregated from CMS SPUF + commercial PBM formularies. Specific rules vary by plan; confirm with your insurer.
| Payer | PA | Step therapy | Copay tier |
|---|---|---|---|
— Medicare Part D | — | — | — |
— Medicare Part D | — | — | — |
— Medicare Part D | — | — | — |
— Medicare Part D | — | — | — |
— Medicare Part D | — | — | — |
— Medicare Part D | — | — | — |
— Medicare Part D | — | — | — |
— Medicare Part D | — | — | — |
— Medicare Part D | — | — | — |
— Medicare Part D | — | — | — |
Showing 10 of 15 PA rules for Secondary Hyperparathyroidism drugs. View individual drug pages for complete PA detail.